title: [Effect of various beta-adrenolytic drugs and calcium channel blocker (nifedipine) on selected indicators of calcium-phosphorus metabolism in patients with hyperthyroidism and simple goiter].
abstract: The study was aimed at evaluation of the effect of short-term treatment with one of the six beta adrenolytic drugs (propranolol, metoprolol, atenolol, pindolol, nadolol, acebutolol) and calcium antagonist nifedipine on the values of several parameters of calcium-phosphorus metabolism in 81 patients with hyperthyroidism (14 patients with Graves' disease, and 67 patients with toxic nodular goiter), and 82 patients with simple goiter. The patients studied have been divided into seven groups, each receiving one of the investigated drugs during four days. A significant decrease in the urinary excretion of hydroxyproline was found only in the patients with hyperthyroidism receiving propranolol. This effect of propranolol on hydroxyprolinuria was not related to the degree of lowering of serum T3 concentration observed in these patients.
authors.forename: T
authors.initials: T
authors.lastname: Gasińska
authors.forename: M
authors.initials: M
authors.lastname: Drózdz
authors.forename: M
authors.initials: M
authors.lastname: Izbicka
authors.forename: E
authors.initials: E
authors.lastname: Szydło
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000378:metabolism*; D005260:Female; D006042:Goiter / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D010758:Phosphorus / Q000378:metabolism*
chemical_list: D000319:Adrenergic beta-Antagonists; D010758:Phosphorus; D000469:Alkaline Phosphatase; D009543:Nifedipine; D006909:Hydroxyproline; D002118:Calcium
vernacular_title: Wpływ róznych leków beta-adrenolitycznych oraz blokera kanału wapniowego (nifedypiny) na zachowanie sie wybranych wskaźników przemiany wapniowo-fosforanowej u chorych z nadczynnościa tarczycy i wolem obojetnym.